Gastroenteropancreatic endocrine tumors (GEP-NETs) are relatively uncommon; comprising
approximately 0.5% of all human cancers. Although they often exhibit relatively indolent …

Pancreatic neuroendocrine neoplasms (panNENs) are the second most common epithelial
tumors of the pancreas. Despite improvements in prognostic grading and staging systems, it …

Genomic profiles of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are still
insufficiently understood, and the genetic alterations associated with drug responses have …

High-grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are rare
but have a very poor prognosis and represent a severely understudied class of tumours …

Pancreatic neuroendocrine tumors are rare tumors of the pancreas originating from the islets
of the Langerhans. These tumors comprise 1% to 3% of all newly diagnosed pancreatic …

Background & Aims: Prediction of biological behavior in pancreatic endocrine tumors (PET)
is difficult on histologic criteria alone. The aim of this study was to characterize PET gene …

Background Recent genetic studies have highlighted that alterations in MEN1, chromatin
remodeling genes, and mammalian target of rapamycin (mTOR) pathway genes are the …

Purpose Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) form a rare and
remarkably heterogeneous group of tumors. Therefore, establishing personalized therapies …

Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are heterogeneous
regarding site of origin, biological behavior, and malignant potential. There has been a rapid …

Pancreatic neuroendocrine tumors (PNETs) are rare but are well understood to cover a
broad spectrum of clinical presentation, tumor biology and prognosis. More than 60% of …